IPO Pro - "The Ultimate Resource for IPOs"
Don't risk buying another IPO without IPO Pro.
Get your FREE TRIAL now.
JUNO News
Archived Headlines
- US IPO Weekly Recap: Record 2014 IPO market finishes with a $2 billion cancer biotech 12/19/14
- Juno Therapeutics prices upsized IPO at $24; largest 2014 biotech IPO with $2.2 billion market cap 12/19/14
- Juno Therapeutics significantly boosts IPO price range to $21 to $23 12/16/14
- Week ahead: The 2014 IPO market's final round with 6 IPOs planned for the week of Dec 15 12/15/14
- Double dose of immunotherapy: Bellicum Pharmaceuticals sets terms for $100 million IPO 12/09/14
See more
Cancer immunotherapy biotech Adaptimmune Therapeutics files for a $150 million IPO
Adaptimmune Therapeutics, which is developing cancer immunotherapies based on genetically engineered T-cell receptors, filed on Monday with the SEC to raise up to $150 million in an initial public offering. The Abingdon, United Kingdom-based company, which was founded in 2008 , plans to list on the NASDAQ under the symbol ADAP. Adaptimmune Therapeutics initially filed...read more
Cancer biotech Cellectis sets terms for $129 million IPO
Cellectis, which is developing cancer immunotherapies based on gene-edited CAR T-cells, announced terms for its US offering on Wednesday. The Paris, France-based company plans to raise $129 million by offering 3.5 million ADSs. Its shares currently trade on the Alternext market of the Euronext Paris under the symbol ALCLS and its last share price was €35, or $36.83....read more
Renaissance IPO Index - Notice of March 2015 Quarterly Changes
The Renaissance IPO Index (Ticker: IPOUSA), the underlying index for the Renaissance IPO ETF (Ticker: IPO), will implement the following constituent changes at the market’s close on Friday, March 20, 2015: Additions: Juno Therapeutics Shell Midstream Partners LP Cnova N.V. Removals: Zoetis Norwegian Cruise Line Pinnacle Foods Bright...read more
Gene therapy biotech Spark Therapeutics sets terms for $88 million IPO
Spark Therapeutics, which is developing gene therapy treatments for retinal dystrophies and hematologic disorders, announced terms for its IPO on Tuesday. The Philadelphia, PA-based company plans to raise $88 million by offering 5.5 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Spark Therapeutics would command a fully diluted market value of...read more